Thiol Disulfide Balance and Oxidative Stress Change in Endometrial Polyp Patients
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Antalya, Turkey
- Alanya Training and Research Hospital Gynecology and Obstetrics Department
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
For participants in the control group:
• To be without endometrial polyp
For the polyp group, they were as follows:
- Individuals experiencing menometrorrhagia
- A body mass index (BMI) of 25 or more
- Hypertension
- Endometrial polyps detected via saline infusion ultrasonography
Exclusion Criteria:
- Pregnancy
- Diabetes mellitus
- Pelvic mass
- Malignancy
- The use of Tamoxifen, hormonal contraceptives, or hormone replacement therapy.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
endometrial polyps
Women with endometrial polyp
|
|
control group
Participants in the control group were confirmed to be free of endometrial polyps via TVUSG and saline infusion ultrasonography
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oxidative stress markers
Time Frame: From January 2021 to January 2022
|
Total antioxidant status (μmol Trolox equivalent/ L)
|
From January 2021 to January 2022
|
|
Oxidative stress markers
Time Frame: From January 2021 to January 2022
|
Total oxidant status (μmol H2O2 equivalent/L)
|
From January 2021 to January 2022
|
|
Oxidative stress markers
Time Frame: From January 2021 to January 2022
|
Oxidative stress index (arbitrary unit)
|
From January 2021 to January 2022
|
|
Oxidative stress markers
Time Frame: From January 2021 to January 2022
|
Paraoxonase (U/L)
|
From January 2021 to January 2022
|
|
Oxidative stress markers
Time Frame: From January 2021 to January 2022
|
Arylesterase (Ku/l)
|
From January 2021 to January 2022
|
|
Oxidative stress markers
Time Frame: From January 2021 to January 2022
|
Total thiol (µmol / L)
|
From January 2021 to January 2022
|
|
Oxidative stress markers
Time Frame: From January 2021 to January 2022
|
Native thiol (µmol / L) / alb (g / l)
|
From January 2021 to January 2022
|
|
Oxidative stress markers
Time Frame: From January 2021 to January 2022
|
Disulfide (-S-S-) (µmol / L) / alb (g/l)
|
From January 2021 to January 2022
|
|
Oxidative stress markers
Time Frame: From January 2021 to January 2022
|
Ischemia-modified albumin (u/L)
|
From January 2021 to January 2022
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 10354421-2020/23-8
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.